Abstract
Objective: To identify the effects and optimal dose of guanfacine extended release (GXR) IntunibTM. Methods: From May, 2017, to April, 2018, 48 patients with ADHD who were treated in our clinic with GXR (24 patients: GXR alone, 24 patients: GXR in combination with other drugs) were retrospectively analyzed. All patients were evaluated by using a multidimensional scale for PDD and ADHD (MSPA) and the ADHD-Rating Scale (RS), and the differences between GXR-effective and -ineffective patients were compared. The factors affecting the efficacy and dosage of GXR were investigated in all patients including those treated with concomitant drugs and the patients treated with GXR alone. Results: RS hyperactivity scores and MSPA hyperactivity scores were significantly higher in GXR-effective patients. In addition, although a significant negative correlation was observed between the optimal dose and the MSPA sensory scores, the correlation disappeared when GXR was used in combination with MPH. Conclusion: The history of hyperactivity was important to predict the effectiveness of GXR. GXR dosage tended to be lower in patients with previous stronger sensory hypersensitivity. It was suggested that the side effects of GXR may be reduced in combination with MPH.
